POPCaP Act of 2026
Sponsored By: Senator Moran, Jerry [R-KS]
Introduced
Summary
Precision oncology program for prostate cancer would be created inside the Department of Veterans Affairs. It would fund a network of Centers of Excellence, genetic sequencing, a national registry, and coordinated clinical trials.
Show full summary
- Veterans: Veterans diagnosed with prostate cancer would be eligible to join the program and could access tumor genetic sequencing, travel support for mutation-targeted studies, and enrollment in VA clinical studies.
- VA medical centers: At least 21 Centers of Excellence would operate, with at least one in each Veterans Integrated Service Network (VISN), designated for five-year terms and subject to performance reviews beginning in 2030.
- Researchers and partners: A Program Leadership team would run a shared registry and data repository, coordinate with the National Cancer Institute and industry, support hybrid decentralized trials, and mentor VA investigators.
*Would authorize $15.5 million per year for fiscal years 2027 through 2029 to establish and begin operations of the Program.*
Personalized for You
How does this bill affect your finances?
Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
New VA precision prostate cancer program
If enacted, the VA would set up a Precision Oncology Program for prostate cancer by January 1, 2027. The program leadership would be based at the Seattle VA Medical Center. The leadership team would include an Executive Director, a Clinical Director, and a Research Director. The team would run research, create a prostate cancer registry, and support hybrid clinical trials. Veterans diagnosed with prostate cancer would be eligible to participate in the program.
Rules for VA prostate cancer centers
If enacted, the VA would immediately designate a set of VA hospitals as Centers of Excellence for the program. The VA must keep at least 21 centers operating and at least one center in each VISN. Each center would be designated for at least five years. Centers would run genetic sequencing for advanced prostate cancer on a uniform platform and join a national registry. Centers would offer metastasis biopsies, telemedicine tumor boards, travel support for veterans with actionable mutations, and develop biomarker trials. Each center must employ at least a medical oncologist, interventional radiologist, urologist, radiation oncologist, pathologist, and two full-time research staff. Starting in 2030, the VA would begin rolling performance reviews and could terminate a center after giving 60 days' notice to Congress.
Funding and reporting for the program
If enacted, the VA Secretary would send an implementation plan within 180 days after enactment. The plan would cover staffing, contracting, sequencing platform choice, registry creation, central IRB coordination, and funding needs for the next 10 years. The VA would give annual reports to Veterans' Affairs and Appropriations committees by March 1 each year. Reports must show funding by center, number of veterans served, study enrollments, investigator counts, publications, and five-year survival comparisons. The bill would authorize $15,500,000 per year for each of fiscal years 2027 through 2029.
Sponsors & CoSponsors
Sponsor
Moran, Jerry [R-KS]
KS • R
Cosponsors
Sen. King, Angus S., Jr. [I-ME]
ME • I
Sponsored 7/29/2026
Roll Call Votes
No roll call votes available for this bill.
View on Congress.gov